{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T09:48:33Z","timestamp":1782899313516,"version":"3.54.5"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017363","name":"Hangzhou Agriculture and Social Development Research Funds","doi-asserted-by":"publisher","award":["20241203A19"],"award-info":[{"award-number":["20241203A19"]}],"id":[{"id":"10.13039\/100017363","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82304517"],"award-info":[{"award-number":["82304517"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373895"],"award-info":[{"award-number":["82373895"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.phrs.2025.108027","type":"journal-article","created":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T01:54:02Z","timestamp":1762566842000},"page":"108027","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["CDC7 stabilized by KRAS signaling reactivation impairs chemosensitivity in KRAS-mutant colorectal cancer"],"prefix":"10.1016","volume":"222","author":[{"given":"Ruilin","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junwei","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianhua","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronggui","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaojun","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2025.108027_bib1","first-page":"229","article-title":"Global cancer statistics 2022: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA A Cancer J. Clin."},{"key":"10.1016\/j.phrs.2025.108027_bib2","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1158\/0008-5472.CAN-19-3682","article-title":"The frequency of ras mutations in cancer","volume":"80","author":"Prior","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2025.108027_bib3","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s12943-021-01441-4","article-title":"Role of oncogenic kras in the prognosis, diagnosis and treatment of colorectal cancer","volume":"20","author":"Zhu","year":"2021","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.phrs.2025.108027_bib4","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1158\/2159-8290.CD-20-0187","article-title":"Egfr blockade reverts resistance to kras(g12c) inhibition in colorectal cancer","volume":"10","author":"Amodio","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.phrs.2025.108027_bib5","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41392-021-00534-2","article-title":"Mutant kras triggers functional reprogramming of tumor-associated macrophages in colorectal cancer","volume":"6","author":"Liu","year":"2021","journal-title":"Signal Transduct. Target Ther."},{"key":"10.1016\/j.phrs.2025.108027_bib6","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1158\/2159-8290.CD-21-1331","article-title":"Expanding the reach of precision oncology by drugging all kras mutants","volume":"12","author":"Hofmann","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.phrs.2025.108027_bib7","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/S0140-6736(19)32319-0","article-title":"Colorectal cancer","volume":"394","author":"Dekker","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2025.108027_bib8","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41392-020-0116-z","article-title":"Comprehensive review of targeted therapy for colorectal cancer","volume":"5","author":"Xie","year":"2020","journal-title":"Signal Transduct. Target Ther."},{"key":"10.1016\/j.phrs.2025.108027_bib9","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1001\/jama.2021.0106","article-title":"Diagnosis and treatment of metastatic colorectal cancer: a review","volume":"325","author":"Biller","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.phrs.2025.108027_bib10","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s44178-025-00152-w","article-title":"Colorectal cancer: highlight the clinical research current progress","volume":"4","author":"Wang","year":"2025","journal-title":"Holist. Integr. Oncol."},{"key":"10.1016\/j.phrs.2025.108027_bib11","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s13045-021-01127-w","article-title":"Emerging strategies to target ras signaling in human cancer therapy","volume":"14","author":"Chen","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.phrs.2025.108027_bib12","article-title":"Sers characterization of colorectal cancer cell surface markers upon anti-egfr treatment","volume":"2","author":"Lyu","year":"2022","journal-title":"Exploration (Beijing)"},{"key":"10.1016\/j.phrs.2025.108027_bib13","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1056\/NEJMoa2212419","article-title":"Adagrasib with or without cetuximab in colorectal cancer with mutated kras g12c","volume":"388","author":"Yaeger","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2025.108027_bib14","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","article-title":"Kras(g12c) inhibition with sotorasib in advanced solid tumors","volume":"383","author":"Hong","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2025.108027_bib15","doi-asserted-by":"crossref","unstructured":"Stanland L.J., Huggins H.P., Sahoo S.S., Porrello A., Chareddy Y., Azam S.H., et al. A first-in-class egfr-directed kras g12v selective inhibitor. Cancer Cell 2025.","DOI":"10.1016\/j.ccell.2025.05.016"},{"key":"10.1016\/j.phrs.2025.108027_bib16","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.ccell.2024.06.001","article-title":"Anti-tumor efficacy of hrs-4642 and its potential combination with proteasome inhibition in kras g12d-mutant cancer","volume":"42","author":"Zhou","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.phrs.2025.108027_bib17","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.trecan.2024.11.009","article-title":"Kras inhibitors: resistance drivers and combinatorial strategies","volume":"11","author":"Isermann","year":"2025","journal-title":"Trends Cancer"},{"key":"10.1016\/j.phrs.2025.108027_bib18","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1158\/2159-8290.CD-24-0177","article-title":"Mechanisms of resistance to oncogenic kras inhibition in pancreatic cancer","volume":"14","author":"Dilly","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.phrs.2025.108027_bib19","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1038\/s41591-024-02903-0","article-title":"Targeting kras in cancer","volume":"30","author":"Singhal","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.phrs.2025.108027_bib20","first-page":"22","article-title":"Colon cancer, version 3.2024, nccn clinical practice guidelines in oncology","author":"Benson","year":"2024","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.phrs.2025.108027_bib21","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3389\/fgene.2015.00116","article-title":"Global impact of kras mutation patterns in folfox treated metastatic colorectal cancer","volume":"6","author":"Zocche","year":"2015","journal-title":"Front. Genet."},{"key":"10.1016\/j.phrs.2025.108027_bib22","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1038\/s41467-022-30576-1","article-title":"The structural basis of cdc7-dbf4 kinase dependent targeting and phosphorylation of the mcm2-7 double hexamer","volume":"13","author":"Saleh","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phrs.2025.108027_bib23","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.neo.2018.08.001","article-title":"Ddk has a primary role in processing stalled replication forks to initiate downstream checkpoint signaling","volume":"20","author":"Sasi","year":"2018","journal-title":"Neoplasia"},{"key":"10.1016\/j.phrs.2025.108027_bib24","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S1097-2765(02)00799-2","article-title":"An atr- and cdc7-dependent dna damage checkpoint that inhibits initiation of dna replication","volume":"11","author":"Costanzo","year":"2003","journal-title":"Mol. Cell"},{"key":"10.1016\/j.phrs.2025.108027_bib25","doi-asserted-by":"crossref","first-page":"7490","DOI":"10.1038\/s41467-023-43274-3","article-title":"Cdc7 inhibition induces replication stress-mediated aneuploid cells with an inflammatory phenotype sensitizing tumors to immune checkpoint blockade","volume":"14","author":"Morita","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phrs.2025.108027_bib26","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/s41392-024-01908-y","article-title":"Cdc7 inhibition impairs neuroendocrine transformation in lung and prostate tumors through myc degradation","volume":"9","author":"Quintanal-Villalonga","year":"2024","journal-title":"Signal Transduct. Target Ther."},{"key":"10.1016\/j.phrs.2025.108027_bib27","article-title":"Cdc7 inhibition potentiates antitumor efficacy of parp inhibitor in advanced ovarian cancer","volume":"11","author":"Liu","year":"2024","journal-title":"Adv. Sci. (Weinh)"},{"key":"10.1016\/j.phrs.2025.108027_bib28","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/s13073-021-00981-0","article-title":"Targeting cdc7 potentiates atr-chk1 signaling inhibition through induction of dna replication stress in liver cancer","volume":"13","author":"Guo","year":"2021","journal-title":"Genome Med."},{"key":"10.1016\/j.phrs.2025.108027_bib29","doi-asserted-by":"crossref","first-page":"v3660","DOI":"10.1126\/sciadv.aav3660","article-title":"Molecular mechanism and potential target indication of tak-931, a novel cdc7-selective inhibitor","volume":"5","author":"Iwai","year":"2019","journal-title":"Sci. Adv."},{"key":"10.1016\/j.phrs.2025.108027_bib30","article-title":"Mapk signaling-mediated rfng phosphorylation and nuclear translocation restrain oxaliplatin-induced apoptosis and ferroptosis","volume":"11","author":"Di","year":"2024","journal-title":"Adv. Sci. (Weinh)"},{"key":"10.1016\/j.phrs.2025.108027_bib31","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s10637-019-00776-6","article-title":"Phase ib study of the mek inhibitor cobimetinib (gdc-0973) in combination with the pi3k inhibitor pictilisib (gdc-0941) in patients with advanced solid tumors","volume":"38","author":"Shapiro","year":"2020","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.phrs.2025.108027_bib32","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s11523-020-00714-0","article-title":"Phase ib trial of the pi3k inhibitor copanlisib combined with the allosteric mek inhibitor refametinib in patients with advanced cancer","volume":"15","author":"Ramanathan","year":"2020","journal-title":"Target Oncol."},{"key":"10.1016\/j.phrs.2025.108027_bib33","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1038\/s41467-022-29070-5","article-title":"Structural insight into the mcm double hexamer activation by dbf4-cdc7 kinase","volume":"13","author":"Cheng","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phrs.2025.108027_bib34","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1038\/s41467-020-15694-y","article-title":"Genotoxic stress triggers the activation of ire1alpha-dependent rna decay to modulate the dna damage response","volume":"11","author":"Dufey","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phrs.2025.108027_bib35","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1006\/scbi.1998.0095","article-title":"P53-dependent cell cycle control: response to genotoxic stress","volume":"8","author":"Schwartz","year":"1998","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.phrs.2025.108027_bib36","unstructured":"Lenferink A.E., Busse D., Flanagan W.M., Yakes F.M., Arteaga C.L. Erbb2\/neu kinase modulates cellular p27(kip1) and cyclin d1 through multiple signaling pathways 2001."},{"key":"10.1016\/j.phrs.2025.108027_bib37","doi-asserted-by":"crossref","unstructured":"Nangia V., Ashraf H., Marikar N., Passanisi V.J., Ill C.R., Spencer S.L. Mapk and mtorc1 signaling converge to drive cyclin d1 protein production to enable cell cycle reentry in melanoma persister cells 2025.","DOI":"10.1101\/2025.05.14.653869"},{"key":"10.1016\/j.phrs.2025.108027_bib38","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1002\/cac2.12192","article-title":"Integrative proteomics reveals the role of e3 ubiquitin ligase syvn1 in hepatocellular carcinoma metastasis","volume":"41","author":"Ji","year":"2021","journal-title":"Cancer Commun. (Lond)"},{"key":"10.1016\/j.phrs.2025.108027_bib39","doi-asserted-by":"crossref","first-page":"n4180","DOI":"10.1126\/science.abn4180","article-title":"Modulation of the proteostasis network promotes tumor resistance to oncogenic kras inhibitors","volume":"381","author":"Lv","year":"2023","journal-title":"Science"},{"key":"10.1016\/j.phrs.2025.108027_bib40","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/sj.emboj.7601490","article-title":"Cytoplasmic destruction of p53 by the endoplasmic reticulum-resident ubiquitin ligase 'synoviolin'","volume":"26","author":"Yamasaki","year":"2007","journal-title":"EMBO J."},{"key":"10.1016\/j.phrs.2025.108027_bib41","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2403038121","article-title":"Er-associated degradation ligase hrd1 links er stress to dna damage repair by modulating the activity of dna-pkcs","volume":"121","author":"Xiang","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2025.108027_bib42","doi-asserted-by":"crossref","first-page":"W739","DOI":"10.1093\/nar\/gkac382","article-title":"Synergyfinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples","volume":"50","author":"Ianevski","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.phrs.2025.108027_bib43","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1056\/NEJMoa2308795","article-title":"Sotorasib plus panitumumab in refractory colorectal cancer with mutated kras g12c","volume":"389","author":"Fakih","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2025.108027_bib44","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1200\/JCO.2015.63.9674","article-title":"Extended ras gene mutation testing in metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy: American society of clinical oncology provisional clinical opinion update 2015","volume":"34","author":"Allegra","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2025.108027_bib45","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJMoa1305275","article-title":"Panitumumab-folfox4 treatment and ras mutations in colorectal cancer","volume":"369","author":"Douillard","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2025.108027_bib46","first-page":"1","article-title":"A review of the evolution of systemic chemotherapy in the management of colorectal cancer","volume":"14","author":"Gustavsson","year":"2015","journal-title":"Clin. Colorectal Cancer"},{"key":"10.1016\/j.phrs.2025.108027_bib47","first-page":"7","article-title":"A cdc7 inhibitor sensitizes dna-damaging chemotherapies by suppressing homologous recombination repair to delay dna damage recovery","author":"Iwai","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.phrs.2025.108027_bib48","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/s41586-022-04698-x","article-title":"Cdc7-independent g1\/s transition revealed by targeted protein degradation","volume":"605","author":"Suski","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2025.108027_bib49","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.7150\/ijbs.57871","article-title":"Characteristics of the pi3k\/akt and mapk\/erk pathways involved in the maintenance of self-renewal in lung cancer stem-like cells","volume":"17","author":"Li","year":"2021","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.phrs.2025.108027_bib50","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1158\/2767-9764.CRC-22-0277","article-title":"Safety, tolerability, and pharmacokinetics of tak-931, a cell division cycle 7 inhibitor, in patients with advanced solid tumors: a phase i first-in-human study","volume":"2","author":"Kuboki","year":"2022","journal-title":"Cancer Res. Commun."},{"key":"10.1016\/j.phrs.2025.108027_bib51","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/s41586-022-04698-x","article-title":"Cdc7-independent g1\/s transition revealed by targeted protein degradation","volume":"605","author":"Suski","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2025.108027_bib52","first-page":"cd47","article-title":"Targeting man1b1 potently enhances bladder cancer antitumor immunity via deglycosylation of","volume":"45","author":"Zhang","year":"2025","journal-title":"Cancer Commun. (Lond)"},{"key":"10.1016\/j.phrs.2025.108027_bib53","doi-asserted-by":"crossref","first-page":"30029","DOI":"10.1074\/jbc.M703705200","article-title":"Identification and characterization of human cdc7 nuclear retention and export sequences in the context of chromatin binding","volume":"282","author":"Kim","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2025.108027_bib54","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1080\/15384101.2016.1176658","article-title":"Cdk1-mediated phosphorylation of cdc7 suppresses dna re-replication","volume":"15","author":"Knockleby","year":"2016","journal-title":"Cell Cycle"},{"key":"10.1016\/j.phrs.2025.108027_bib55","doi-asserted-by":"crossref","first-page":"12041","DOI":"10.1074\/jbc.M512630200","article-title":"Importin-beta mediates cdc7 nuclear import by binding to the kinase insert ii domain, which can be antagonized by importin-alpha","volume":"281","author":"Kim","year":"2006","journal-title":"J. Biol. Chem."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661825004529?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661825004529?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T14:35:24Z","timestamp":1773326124000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661825004529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":55,"alternative-id":["S1043661825004529"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2025.108027","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CDC7 stabilized by KRAS signaling reactivation impairs chemosensitivity in KRAS-mutant colorectal cancer","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2025.108027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108027"}}